Genomic Vision: Financial Information for the First Half of 2022
22 Juli 2022 - 6:29PM
Business Wire
- Revenue up 9.4%
- Revenues from activity up 5.8%
- Cash at June 30, 2022 at €1.0m
Regulatory News:
Genomic Vision (FR0011799907 - GV, PEA-PME eligible)
(Paris:GV), a biotechnology company developing tools and
services dedicated to the analysis and control of genome
modifications, today announced its first half revenues and cash
position at June 30, 2022.
H1 2022 (unaudited figures)
In € thousands - IFRS data
H1 2022
H1 2021
Revenue from sales
511
467
Other revenue
232
235
Total revenue from activity
743
702
Revenue from sales for the first half of 2022 amounted to
€511 thousand, up 9.4% compared to the first half of 2021. This
increase in sales of products and services reflects the efforts
made in commercial prospecting. It should be noted that no platform
sales were made during the first half of the year.
Total revenue from activity in the first half of 2022,
after taking into account other revenue, is up by 5.8% compared to
the same period in 2021. Other income, amounting to €232 thousand
in the first half of 2022, corresponds to the research tax
credit.
Financial structure at June 30, 2022
Genomic Vision had a cash position of €1.0 million at June 30,
2022, compared to €1.3 million at March 31, 2022. This decline is
linked to the delay in the implementation of the new financing
agreement with Winance signed on April 11, 2022 and ratified by the
extraordinary general meeting of May 23, 2022.
The new financing line, now implemented, corresponds to a
maximum of 15 tranches of €2 million nominal value each, i.e. up to
€30 million. It will cover additional working capital requirements
to support Genomic Vision's commercial development over the next
three years.
Upcoming financial publications
- H1 2022 results: Thursday, September 29, 2022
- Q3 2022 revenue: Thursday, October 27, 2022
***
ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company developing products
and services dedicated to the analysis (structural and functional)
of genome modifications as well as to the quality and safety
control of these modifications, in particular in genome editing
technologies and biomanufacturing processes. Genomic Vision
proprietary tools, based on DNA combing technology and artificial
intelligence, provide robust quantitative measurements needed to
high confidence characterization of DNA alteration in the genome.
These tools are mainly used for monitoring DNA replication in
cancerous cell, for early cancer detection and the diagnosis of
genetic diseases. Genomic Vision, based near Paris in Bagneux, is a
public listed company listed in compartment C of Euronext’s
regulated market in Paris (Euronext: GV – ISIN: FR0011799907).
For further information, please visit www.genomicvision.com
***
Member of the CAC® Mid & Small and CAC®
All-Tradable indexes
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business. Such forward-looking statements are based on assumptions
that Genomic Vision considers to be reasonable. However, there can
be no assurance that such forward-looking statements will be
verified, which statements are subject to numerous risks, including
the risks set forth in the “Risk Factors” section of the universal
registration document filed with the AMF on April 14, 2022 under
reference number R.22-0293, as updated by the amendment filed with
the AMF on May 20, 2022, under number D.22-0293-A01, available on
the web site of Genomic Vision (www.genomicvision.com) and to the
development of economic conditions, financial markets and the
markets in which Genomic Vision operates. The forward-looking
statements contained in this press release are also subject to
risks not yet known to Genomic Vision or not currently considered
material by Genomic Vision. The occurrence of all or part of such
risks could cause actual results, financial conditions, performance
or achievements of Genomic Vision to be materially different from
such forward-looking statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220722005399/en/
Genomic Vision Aaron Bensimon CEO Tel.: +33 1 49 08 07 51
investisseurs@genomicvision.com
Ulysse Communication Press Relations Bruno Arabian
Tel.: +33 1 42 68 29 70 barabian@ulysse-communication.com
NewCap Investor Relations & Strategic
Communications Tel.: +33 1 44 71 94 94 gv@newcap.eu
Goldfield (AMEX:GV)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Goldfield (AMEX:GV)
Historical Stock Chart
Von Jun 2023 bis Jun 2024